ALK-Abelló — Major Shareholding Notification 2016

Jan 15, 2016

ALK

Company release No 3/2016

Hørsholm
15 January 2016

Notification of ownership in ALK

Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has received notification from Invesco Limited, that Invesco Canada Ltd. has reduced its ownership in ALK-Abelló A/S to below 5% of the share capital.

Invesco Canada Ltd. now owns 4.8% of the company share capital equivalent to 486,615 B shares.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 1,900 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and Seqirus (previously bioCSL) to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.

Company release No 3/2016 – 15 January 2016

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk.net

Tel +45 4574 7576 – CVR No 63 71 79 16